Ritlecitinib Tosilate

• A Long-Term Extension Study to Evaluate the Safety and Efficacy of Ritlecitinib in Participants With Severe AA Who Have Completed Studies B7… Pending
  2024-515439-31-00 Phase III 5 countries Pfizer Inc.
• A Phase 3 Study With Randomized Withdrawal/Dose Up Investigating the Efficacy, Safety, and Tolerability of Ritlecitinib in Participants With… Recruiting
  2023-505804-42-00 Phase III 5 countries Pfizer Inc.
• A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medic… Recruiting
  2025-522705-37-00 Phase II 4 countries Pfizer Inc.
• A Study to Learn About the Study Medicine Called Ritlecitinib in People With Hives Without a Known Cause Recruiting
  2025-522642-44-00 Phase II 4 countries Pfizer Inc.
• A Phase 3 Study to Evaluate the Efficacy and Safety of Ritlecitinib in Children 6 to <12 Years of Age With Severe Alopecia Areata Ended
  2024-515438-33-00 Phase III 5 countries Pfizer Inc.
• A Study of Two Doses of Ritlecitinib in People 12 Years of Age and Older with Alopecia Areata Ended
  2024-519370-40-00 Phase III 3 countries Pfizer Inc.
• A Phase 3 Placebo-Controlled Study With Randomized Dose Up/Dose Down Extension Period Investigating the Efficacy, Safety, and Tolerability o… Ended
  2022-502518-98-00 Phase III 8 countries Pfizer Inc.
• A Phase 3 Study Investigating the Efficacy, Safety, and Tolerability of Ritlecitinib in Participants with Nonsegmental Vitiligo Ended
  2022-501668-16-00 Phase III 5 countries Pfizer Inc.
• A Phase 1 Study Evaluating Relative Bioavailability of Sprinkled Ritlecitinib in Applesauce, Yoghurt, and Strawberry Jam and Evaluating the … Ended
  2022-502872-22-00 Phase I (Other) 1 country Pfizer Inc.
• Long-Term PF-06651600 for the Treatment of Alopecia Areata (ALLEGROLT) Ended
  2023-509801-59-00 Phase III 4 countries Pfizer Inc.

Showing 1–10 of 10 trials